People With Diabetes Regularly Receiving Sulfonylureas
Identifying Attributes
Care Settings
Primary Care
Country
New Zealand
Publishing Organisation
Health Quality & Safety Commission
Type of Quality Indicator
Process
IOM Quality Dimension
Effectiveness
Domain
Medications and Medication Management
Defining Attributes
Definition
This indicator shows the number and percent of people with diabetes receiving sulfonylureas (glibenclamide, gliclazide and glipizide) regularly.
Numerator
People with diabetes dispensed sulfonylureas in three or four quarters in the relevant year.
Denominator
Count of distinct master NHIs identified as having diabetes as per the Virtual Diabetes Register.
Exclusions
None
Use of Risk Adjustment
No
Risk Adjustments
None
Stratifications
By year, age group (0-14, 15-24, 25-44, 45-64, 65-74, 75+), gender, ethnic group, PHO group and Health New Zealand district of domicile.
Collection and Reporting Attributes
Type of Data Collection
Standardised clinical data
Data Collection Methods
Pharmaceutical Collection, Virtual Diabetes Register.
Frequency of Data Collection
Frequency of Data Collection in Days
Reporting Methods
Atlas of Healthcare Variation website
Reporting Frequency
Annually
Reporting Frequency in Days
365
Indicator Has Recommended Targets
No
Source and Reference Attributes
Technical Specifications
Link to Measurement Tools
Quality Indicator Confirmed to be Part of a Program Used to Monitor Quality and Safety of Care Among Older People at a Population-Level between 2012-2022
Yes
Assessed by the Australian Consortium for Aged Care Collaborators as Generally Containing Good Properties (Importance and Scientific Acceptability)
No
Australian Consortium for Aged Care Endorsed
No
Identified by PHARMA-Care Project
No
Upload Date
02 December 2025
Contents
Actions
Date Modified 02 December 2025